GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4623)

  • GC79383 structure
    GC79383Anti-Mouse IL-17A Antibody (BZN035)
    Purity: >97.50%

    Anti-Mouse IL-17A Antibody (BZN035) is an antibody targeting mouse IL-17A, which binds to and neutralizes the activity of mouse IL-17A.

  • GC79384 structure
    GC79384TSLP-IN-1
    CAS: 512837-95-5
    Purity: >99.50%

    TSLP-IN-1 is a potent thymic stromal lymphopoietin ( TSLP ) inhibitor.

  • GC79385 structure
    GC79385Anti-Mouse IL-4Rα Antibody (REGN1103)
    Purity: >99.50%

    Anti-Mouse IL-4Rα Antibody (REGN1103) is a mouse homologous antibody targeting IL-4Rα, as well as an inhibitor of IL-4 signaling.

  • GC79386 structure
    GC79386Anti-Mouse IL-2 Antibody (JES6-5H4)
    Purity: >98.50%

    Anti-Mouse IL-2 Antibody (JES6-5H4) reacts with mouse IL-2 that can neutralize IL-2 in vivo.

  • GC79389 structure
    GC79389ETI41
    CAS: 2773474-99-8
    Purity: >98%

    ETI41 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 ( IC 50 = 0.63 μM) and TLR9 ( IC 50 = 0.16 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5).

  • GC79390 structure
    GC79390ETI60
    CAS: 2773475-11-7
    Purity: >99.50%

    ETI60 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 ( IC 50 = 0.68 μM) and TLR9 ( IC 50 = 0.12 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5).

  • GC79391 structure
    GC79391MyD88-IN-3
    Purity: >99.00%

    MyD88-IN-3 is an orally active, selective MyD88 Inhibitor.

  • GC79393 structure
    GC79393PY109
    CAS: 2378039-23-5
    Purity: >99.00%

    PY109 is an orally active and highly selective aryl hydrocarbon receptor ( AHR ) agonist.

  • GC79394 structure
    GC79394IL4RPep-1 acetate
    Purity: >98.50%

    IL4RPep-1 acetate is an interleukin-4 receptor ( IL-4R ) binding agent.

  • GC79395 structure
    GC79395NT-0527
    CAS: 2771019-10-2
    Purity: >99.50%

    NT-0527 is a selective, orally active, and brain-permeable NLRP3 inflammasome inhibitor.

  • GC79396 structure
    GC79396Anti-CD3 Antibody (UCHT-1)
    Purity: >97.00%

    Anti-CD3 Antibody (UCHT-1) is an antibody targeting CD3.

  • GC79397 structure
    GC793972'2'-cGAMP disodium
    Purity: >99.50%

    2'2'-cGAMP disodium, a synthetic CDN, binds STING in the immune response, inducing IFN-β. 2'2'-cGAMP disodium binds weaker binding to STING than 2'3'-cGAMP but stronger than other CDNs [1] .

  • GC79398 structure
    GC79398Elfritatug
    CAS: 3058391-18-4
    Purity: >98.50%

    Elfritatug (UCB4594) is a humanized monoclonal antibody targeting human leukocyte antigen-G ( HLA-G ).

  • GC79401 structure
    GC79401WT1 126-134 peptide acetate
    Purity: >99.00%

    WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein ( WT1 ) peptide (RMFPNAPYL).

  • GC79402 structure
    GC79402Anti-pan MHC Class II (HLA II) Antibody (IVA12)
    Purity: >99.00%

    Anti-pan MHC Class II (HLA II) Antibody (IVA12) recognizes human HLA-II (HLA-DR, HLA-DP, and HLA-DQ).

  • GC79403 structure
    GC79403Anti-Mouse MHC Class I (H-2Kb/H-2Db) Antibody
    Purity: >98.00%

    Anti-Mouse MHC Class I (H-2Kb/H-2Db) Antibody (28-8-6S) reacts with the mouse H-2Kb and H-2Db MHC Class I alloantigens.

  • GC79405 structure
    GC79405TSLP modulator-1
    Purity: >99.50%

    TSLP modulator-1 (Compound 14O) is a potent TSLP signaling modulator.

  • GC79406 structure
    GC79406SMU-Z1
    CAS: 2410782-66-8
    Purity: >99.00%

    SMU-Z1 is a TLR1/2 heterodimer agonist with an EC 50 of 4.88 nM.

  • GC79407 structure
    GC79407Anti-Mouse CD20 Antibody (18B12)
    Purity: >99.00%

    Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20.

  • GC79408 structure
    GC79408NOS-IN-4
    CAS: 3737-39-1
    Purity: >97.00%

    NOS-IN-4 (Compound 3) is a neuronal nitric oxide synthase ( nNOS ) inhibitor with an IC 50 of 4.00 μM that inhibits nNOS activity.

  • GC79409 structure
    GC79409Pulchinenoside K
    CAS: 1257378-28-1
    Purity: >98%

    Pulchinenoside K (Compound 4) is a triterpenoid saponin.

  • GC79410 structure
    GC79410(rac)-NDT-19795
    CAS: 2272918-42-8
    Purity: >99.00%

    (rac)-NDT-19795 is the racemate of NDT-19795.

  • GC79411 structure
    GC79411TN-783
    Purity: >98%

    TN-783 is an orally active, brain-penetrant NLRP3 ( IC 50 = 19.3 nM) inhibitor.

  • GC79412 structure
    GC79412IIIM-1270
    CAS: 4818-19-3
    Purity: >98.50%

    IIIM-1270is a NLRP3 inflammasome inhibitor.